Artal Group S.A. Aeglea Bio Therapeutics, Inc. Transaction History

Artal Group S.A.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 12, 2022	SELL	$1.87 - $4.77 $1.95 Million - $4.98 Million	-1,045,000 Closed	0 $0
Q3 2020 Nov 13, 2020	SELL	$6.51 - $9.33 $358,050 - $513,150	-55,000 Reduced 5.0%	1,045,000 $7.41 Million
Q2 2020 Aug 14, 2020	BUY	$4.01 - $11.04 $2.81 Million - $7.73 Million	700,000 Added 175.0%	1,100,000 $10.2 Million
Q1 2020 May 14, 2020	BUY	$3.51 - $8.48 $351,000 - $848,000	100,000 Added 33.33%	400,000 $1.86 Million
Q3 2019 Nov 14, 2019	BUY	$6.42 - $9.0 $841,315 - $1.18 Million	131,046 Added 77.56%	300,000 $2.31 Million
Q2 2019 Aug 09, 2019	BUY	$6.1 - $8.78 $1.03 Million - $1.48 Million	168,954 New	168,954 $1.16 Million

241K

Ticker AGLE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,172,500
Market Cap $1.69B
Description
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy f...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.